Depletion of B lymphocytes from cerebral perivascular spaces by rituximab
M del Pilar Martin, PD Cravens, R Winger… - Archives of …, 2009 - jamanetwork.com
Background Rituximab is a recombinant chimeric monoclonal antibody against CD20, a
molecule expressed on cells of the B-cell lineage. A phase 2 clinical trial recently provided
strong evidence of the beneficial effects of rituximab in patients with relapsing-remitting
multiple sclerosis. We and other investigators previously demonstrated that rituximab
therapy depletes B lymphocytes from peripheral blood and cerebrospinal fluid of patients
with relapsing-remitting multiple sclerosis. Objective To determine the effect of rituximab on …
molecule expressed on cells of the B-cell lineage. A phase 2 clinical trial recently provided
strong evidence of the beneficial effects of rituximab in patients with relapsing-remitting
multiple sclerosis. We and other investigators previously demonstrated that rituximab
therapy depletes B lymphocytes from peripheral blood and cerebrospinal fluid of patients
with relapsing-remitting multiple sclerosis. Objective To determine the effect of rituximab on …